期刊文献+

A chromatographic method for pursuing potential GPCR ligands with the capacity to characterize their intrinsic activities of regulating downstream signaling pathway

原文传递
导出
摘要 GPCRs are dominant targets for approved drugs and the discovery of lead compound targeting them is still challengeable.Affinity-based screening technique is a promising platform to uncover GPCR ligands.However,the intrinsic activities of them are seldom simultaneously determined during the screening.Taking beta2-adrenoceptor(β2AR)as a probe,this work created a strategy for screening GPCR ligands with simultaneous characterization of their downstream G protein binding responses associated with GTP.The strategy included(i)the design and expression of a protein miniature formed byβ2AR and G proteinα-subunit(Gαs)using circularly permuted HaloTag(cpHalo)as a flexible linker;(ii)immobilization of the miniature onto silica gel by a click dehalogenation reaction;(iii)systematic characterization of the immobilized miniature by fluorescent and chromatographic studies,and(iv)simulating of ligand-inducedβ2AR-Gαs signaling cascade by chromatographic assays using GTP as an indicator.The immobilized miniature exhibited specificity toβ2AR and Gαs antibodies and ligands.The specificity is stable at least within fifteen days with the variation less than 1%.The intrinsic activities ofβ2AR ligands were distinguished by the changes of GTP chromatographic behaviors on Gαs-cpHalo-β2AR column.Agonists strengthened the binding affinity and kinetics of GTP with Gαs,while antagonist did not give any effect on them.With the intrinsic activity evaluation,we believe,it will improve the attributes of chromatographic methods for drug discovery efforts with minimizing false-positive results.
出处 《Chinese Chemical Letters》 SCIE CAS CSCD 2024年第10期425-429,共5页 中国化学快报(英文版)
基金 National Natural Science Foundation of China(Nos.22374116,22074118,82174088) Natural Science Basic Research Program of Shaanxi(2024JC-TBZC-21) Shaanxi Administration of Traditional Chinese Medicine(No.2022-SLRH-YQ-007)。
  • 相关文献

参考文献3

二级参考文献30

  • 1E.C.Rao,J.C.Cheng,G.Z.Yang,et al.Acta Pharm.Sin.29(1994)502.
  • 2W.Z.Duan,J.T.Zhang,Acta Pharm.Sin.33(1998)259.
  • 3W.Z.Duan,J.T.Zhang,Acta Pharmacol.Sin.19(1998)332.
  • 4S.L.Liu,J.T.Zhang,Acta Pharm.Sin.33(1998)254.
  • 5S.L.Liu,M.R.Zhao,J.T.Zhang,Acta Pharm.Sin.34(1999)325.
  • 6C.J.Zhu,J.T.Zhang,Chirality 15(2003)448.
  • 7C.J.Zhu,J.T.Zhang,Chirality 15(2003)668.
  • 8C.J.Zhu,J.T.Zhang,Chirality 21(2009)402.
  • 9Q.Q.Yao,M.Z.Wang,Acta Pharm.Sin.33(1998)296.
  • 10Q.Q.Yao,M.Z.Wang,Acta Pharm.Sin.34(1999)303.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部